Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Health
Pharmaceutical
X-Linked Hypophosphataemia